Ebony Bonner, LSW | |
7232 Justin Way, Mentor, OH 44060-4881 | |
(440) 578-8200 | |
Not Available |
Full Name | Ebony Bonner |
---|---|
Gender | Female |
Speciality | Social Worker |
Location | 7232 Justin Way, Mentor, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790336139 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Ebony Bonner, LSW 7232 Justin Way, Mentor, OH 44060-4881 Ph: (440) 578-8200 | Ebony Bonner, LSW 7232 Justin Way, Mentor, OH 44060-4881 Ph: (440) 578-8200 |
News Archive
Scientists have discovered a new type of immune cell that could predict which lung cancer patients will benefit most from immunotherapy treatment, according to a Cancer Research UK-funded study published today (Monday) in Nature Immunology.
Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the second quarter ended June 30, 2010.
"Jim Yong Kim, the U.S. nominee, seems certain to become the next president of the World Bank after developing countries failed in an effort to unite behind a single candidate," the Financial Times reports, noting, "Jose Antonio Ocampo, the former Colombian finance minister, withdrew from contention and endorsed Ngozi Okonjo-Iweala, the Nigerian finance minister, after she won wider support among a group of developing countries on Friday."
HHS this week awarded $109 million to states to strengthen the review process for proposed increases in health insurance premiums. Politico reports that some of the funding also went to consumer advocacy groups that often take on insurers. Meanwhile, California Healthline details what funding its home state secured.
The international consortium A-PARADDISE (Anti-Parasitic Drug Discovery in Epigenetics), coordinated by Inserm, has just obtained funds of €6 million from the European Commission to conduct large-scale testing of innovative therapies against four neglected parasitic diseases: schistosomiasis, leishmaniasis, Chagas disease and malaria.
› Verified 8 days ago